Robert Coleman, MD
Enriched profileChief Medical Officer, Vaniam Group (inaugural, appointed May 2023); also practicing gynecologic oncologist at Texas Oncology–The Woodlands · Vaniam Group
Robert Coleman is Chief Medical Officer, Vaniam Group (inaugural, appointed May 2023); also practicing gynecologic oncologist at Texas Oncology–The Woodlands at Vaniam Group. OpenAlex indexes 1,362 publications with 53,393 citations (h-index 105); ClinicalTrials.gov lists 16 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Gynecologic Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Robert L. Coleman is Chief Medical Officer, Vaniam Group (inaugural, appointed May 2023). The public record shows 1,362 publications with 53,393 citations (h-index 105), centered on Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Endometrial and Cervical Cancer Treatments. It also documents an investigator role on 11 registered clinical trials.
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Ovarian cancer diagnosis and treatment
- 11 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 48 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 471.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sponsor: National Cancer Institute (NCI)
- Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Sponsor: National Cancer Institute (NCI)
Industry payments
42 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202523 payments$41,752openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year202528 payments$25,443openpaymentsdata.cms.gov ↗
- Eisai Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.
JCO precision oncology
Article2026 - An evaluation of avutometinib in combination with defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.
Expert review of anticancer therapy
Review2026 - Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights.
Clinical cancer research
Clinical Trial2026 - Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.
Clinical cancer research
Clinical Trial2026 - Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities.
Clinical cancer research
Review2026
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/robert-coleman-md-73f1f4cb
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/robert-l-coleman-b257b6
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
sciprofiles.com/profile/384030
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sciprofiles.com ↗
Mentions by others
where others cite or feature them- Other
ascopost.com/videos/2018-asco-annual-meeting/robert-coleman-on-ovarian-cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Other
onclive.com/view/coleman-and-slomovitz-continue-the-discussion-on-maintenance-parp-inhibition-in-ovarian-cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ocrahope.org ↗
- M.D.
Creighton University School of Medicine, Omaha, NE
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - Residency
Obstetrics & Gynecology, Northwestern Medicine Prentice Women's Hospital / Northwestern University Medical Center, Chicago, IL
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - Board certified
Gynecologic Oncology and Obstetrics/Gynecology; FACOG (Fellow, American College of Obstetricians and Gynecologists)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vaniamgroup.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →usoncology.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vaniamgroup.com ↗
- Co-Director
GOG-Partners (Gynecologic Oncology Group Partners Foundation), and Board of Directors, GOG-Foundation, Inc.
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vaniamgroup.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vaniamgroup.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →usoncology.com ↗
Secondary affiliations
appointments beyond the home institution- Former Chief Scientific Officer
US Oncology Research (USOR/USRI), and Chief Medical Officer, Sarah Cannon Research Institute (SCRI), a joint-venture research organization
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →usoncology.com ↗ - Former Vice-Chairman
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas; former Assistant Professor, Creighton University
1996verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vaniamgroup.com ↗ - Texas Oncology–The Woodlands
practicing gynecologic oncologist (clinical practice, part of The US Oncology Network)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
Media & interviews
press, podcasts and appearances- IJGC (International Journal of Gynecologic Cancer) podcast guest with Editor-in-Chief Dr. Pedro Ramirez
"Overall Survival of SORAYA Trial with Robert Coleman"
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Sameer Gopalani, MD
Oak Ridge Associated Universities
Baha Sibai, MD
Memorial Hermann
Kathleen Moore, MD
University of Nebraska Medical Center
George Saade, MD
Eastern Virginia Medical School